Treatment selection for first-line metastatic renal cell carcinoma in Australia: Impact of new therapy options

被引：3

作者：

Schmidt, Andrew ^{[1
]}

Azad, Arun ^{[2
]}

Goh, Jeffrey ^{[3
,4
]}

Harris, Carole ^{[5
,6
]}

Joshua, Anthony M. ^{[7
]}

Weickhardt, Andrew ^{[8
]}

Krieger, Laurence ^{[9
]}

机构：

[1] Liz Plummer Canc Ctr, Cairns, Qld, Australia

[2] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[3] Royal Brisbane & Womens Hosp, Butterfield St, Herston, Qld, Australia

[4] Univ Queensland, St Lucia, Qld, Australia

[5] St George Hosp, Kogarah, NSW, Australia

[6] Sutherland Clin Sch UNSW, Kogarah, NSW, Australia

[7] Kinghorn Canc Ctr, Darlinghurst, NSW, Australia

[8] Olivia Newton John Canc Res Inst, Heidelberg, Vic, Australia

[9] Royal North Shore Hosp, Northern Canc Inst, Reserve Rd, St Leonards, NSW, Australia

来源：

ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 15卷

关键词：

immuno-oncology; renal cell carcinoma; VEGF tyrosine kinase inhibitors; INTERFERON-ALPHA; PREEXISTING AUTOIMMUNE; OPEN-LABEL; EVEROLIMUS; SUNITINIB; EFFICACY; SURVIVAL; CANCER; NEPHRECTOMY; LENVATINIB;

D O I：

10.1111/ajco.13289

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Vascular endothelial growth factor receptor tyrosine kinase inhibitors have provided an effective standard of care for the treatment of metastatic clear cell renal cell carcinoma (mRCC). Survival is prolonged with emergence of modern immuno-oncology combination regimens. Prognostic risk assessment is essential for choosing between these therapies to determine the most appropriate first line treatment option, with selection based on International Metastatic RCC Database Consortium Risk Category. We review the current subsidized first line treatments for mRCC in Australia and consider the evidence for treatment selection and sequencing.

引用

页码：3 / 10

页数：8

共 50 条

[1] First-line treatment of metastatic renal cell carcinoma
Bruchbacher, Andreas
Netsch, Christopher
Gross, Andreas J. J.
UROLOGIE, 2023, 62 (08): : 830 - 839
[2] Approaches to First-Line Therapy for Metastatic Clear Cell Renal Cell Carcinoma
Chen, Yu-Wei
Rini, Brian, I
CURRENT ONCOLOGY REPORTS, 2022, 24 (06) : 695 - 702
[3] Current and emerging therapies for first-line treatment of metastatic clear cell renal cell carcinoma
Atkins, Michael B.
Tannir, Nizar M.
CANCER TREATMENT REVIEWS, 2018, 70 : 127 - 137
[4] First-line treatment options in metastatic renal cell cancer
Kapoor, Anil
CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2016, 10 (11-12): : S236 - S238
[5] First-line therapy for metastatic renal cell carcinoma
Sawhney, Paramvir
Suyanto, Suyanto
Michael, Agnieszka
Pandha, Hardev
JOURNAL OF CLINICAL UROLOGY, 2024, 17 (02) : 190 - 200
[6] First-line treatment of metastatic renal cell carcinoma after COMPARZ and PISCES
Schmidinger, Manuela
Wittes, Janet
CURRENT OPINION IN UROLOGY, 2015, 25 (05) : 395 - 401
[7] Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
Vazquez, Sergio
Leon, Luis
Fernandez, Ovidio
Lazaro, Martin
Grande, Enrique
Aparicio, Luis
ADVANCES IN THERAPY, 2012, 29 (03) : 202 - 217
[8] The efficacy of axitinib as a first-line treatment for metastatic renal cell carcinoma
Kameda, Tomohiro
Takayama, Tatsuya
Sugihara, Toru
Takeshima, Saki
Yamazaki, Masahiro
Komatsubara, Maiko
Kamei, Jun
Fujisaki, Akira
Ando, Satoshi
Kurokawa, Shinsuke
Fujimura, Tetsuya
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 (04) : 241 - 246
[9] Tolerability of first-line therapy for metastatic renal cell carcinoma
Porta, Camillo
Szczylik, Cezary
CANCER TREATMENT REVIEWS, 2009, 35 (03) : 297 - 307
[10] Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options
Fitzgerald, Kelly N.
Lee, Chung-Han
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2022, 20 (13):

← 1 2 3 4 5 →